Envoy Medical reaches dismissal in Delaware Chancery litigation with no payment required

Envoy Medical, Inc. (COCH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement

Envoy Medical (NASDAQ: COCH) reported positive 12-month interim results from Stage 1 of its pivotal trial for the investigational fully implanted Acclaim cochlear implant. In 10 participants, mean CNC word recognition rose to 53.2% from a 15.2% baseline. No protocol-defined serious adverse events were reported. Stage 2 is fully enrolled.

Cochin Shipyard shares fell 4.1% to ₹1,445.1 on Tuesday after India’s government announced an Offer for Sale of up to 5.04% of its stake at a floor price of ₹1,400, a >7% discount to the prior day. The OFS supply weighed on the stock; government holds 67.92%.

NVIDIA is investing in both proprietary and open-source AI models, including a $90M Series B round for Nous Research, valuing it at $1.5B. Nous claims its Hermes 4.3 model outperforms GPT-4o in key metrics, but lacks independent verification. The company aims to compete with lower pricing, offering $0.30 per million tokens compared to competitors' higher rates. NVIDIA's strategy ensures its hardware remains central to AI infrastructure regardless of the winning model architecture.

Piper Sandler initiated coverage of LCNB Corp. with a Neutral rating and $20 price target, citing its lower-cost funding, revenue diversity, and regional scarcity. The target is based on 11x 2027 EPS, a premium to peers. LCNB has a P/E of 10.98, a 4.71% dividend yield, and steady loan growth prospects of 2% in 2027, according to Piper Sandler.

Biohaven (BHVN) has licensed its IgG degrader portfolio to Ono Pharma for Asian markets, including Japan and South Korea. The deal includes up to $100M in payments, with Biohaven retaining rights outside these regions. The portfolio, led by BHV-1300 in Phase 3 trials for Graves' disease, aims to treat autoimmune disorders. Biohaven's stock closed at $11.88, up 1.18% in pre-market trading.